European regulators are investigating a possible link between the vaccine and a second rare blood disorder.
- Senior Lecturer in Haematology, Immunolgy, Genetics and Evolution, University of Lancashire
CAR-T is a powerful new immunotherapy for treating leukaemia. We need to build on it to attack other, harder-to-treat cancers.
Contact Peter for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Location: Preston, UK
- X (formerly Twitter): @peteabel
- Article Feed
- ORCID
- Joined
